Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial

BACKGROUND: Myeloma causes profound immunodeficiency and recurrent, serious infections. Around 5500 new cases of myeloma are diagnosed per year in the UK, and a quarter of patients will have a serious infection within 3 months of diagnosis. We aimed to assess whether patients newly diagnosed with my...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Drayson, Mark T, Bowcock, Stella, Planche, Tim, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Wood, Jill, Raynes, Kerry, Higgins, Helen, Dawkins, Bryony, Meads, David, Hulme, Claire T, Monahan, Irene, Karunanithi, Kamaraj, Dignum, Helen, Belsham, Edward, Neilson, Jeff, Harrison, Beth, Lokare, Anand, Campbell, Gavin, Hamblin, Michael, Hawkey, Peter, Whittaker, Anna C, Low, Eric, Dunn, Janet A
Formato: Artigo
Idioma:Inglês
Publicado em: Lancet Pub. Group 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6891230/
https://ncbi.nlm.nih.gov/pubmed/31668592
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(19)30506-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados